首页> 外文学位 >Polyaminobenzamides and related analogues as isoform-selective histone deacetylase inhibitors.
【24h】

Polyaminobenzamides and related analogues as isoform-selective histone deacetylase inhibitors.

机译:聚氨基苯甲酰胺和相关类似物作为同工型选择性组蛋白脱乙酰基酶抑制剂。

获取原文
获取原文并翻译 | 示例

摘要

The remodeling of chromatin between relatively open and closed forms has a key role in epigenetic regulation of gene expression; including numerous genes that mediate tumorigenesis. Such remodeling results from modifying the structure of nucleosome by a range of modifications of the amino-terminal 'tails' of histones. Among them hsitone acetylation and deacetylation by opposing activities of histone aceyltransferase and hsitone deacetylase tightly regulate gene expression through chromatin modification. Aberrant histone deacetylase (HDAC) activity promotes chromatin condensation and inhibits expression of tumor suppressor factors; by contrast, HDAC inhibition caused by HDAC inhibitors such as trichostatin (TSA), MS-275 and SAHA results in tumor growth inhibition in wide range of transformed cells. Traditional HDAC inhibitors lack isoform specificity, and can produce toxicity to noncancerous cells. Hence polyamine derivatives, polyaminohydroxamic acid (PAHA) and polyaminobenzamide (PABA) analogues can be used as HDAC inhibitors to reduce toxicity, increase the affinity for chromatin and to have potential for uptake by the polyamine transporter. Specific interaction of the polyamine moiety with the HDAC rim region could also improve isoform specificity.;First generation of polyamino HDAC inhibitors, PAHAs were synthesized earlier in our laboratory and they were potent HDAC inhibitors, but poor substrates for the transporter. Hence, we designed second generation of polyamino HDAC inhibitors, additional PABA derivatives and isosteric homologues to improve isoform specificity and polyamine transportability. Most of the compounds with various structural features seem to inhibit HDACs in enzyme assay and some of them have shown considerable selectivity for HDAC 1 against HDAC 3, 6 and 8 and in cultured tumor cells. Among this small library of compounds, one compound showed promising cytotoxiciy effect in human breast tumor cells compared to normal breast epithelial cells.;In this dissertation, we report the synthesis of PABAs and isosteric homologues and their activity against HDAC isoforms and their biological evaluation in tumor cells.
机译:染色质在相对开放和封闭形式之间的重塑在基因表达的表观遗传调控中起着关键作用。包括许多介导肿瘤发生的基因。这种重塑是通过对组蛋白的氨基末端“尾巴”进行一系列修饰来修饰核小体的结构而产生的。其中组蛋白乙酰转移酶和组蛋白去乙酰化酶的相反活性引起组蛋白乙酰化和脱乙酰化通过染色质修饰紧密调节基因表达。异常的组蛋白脱乙酰基酶(HDAC)活性促进染色质凝结并抑制肿瘤抑制因子的表达;相比之下,由曲古抑菌素(TSA),MS-275和SAHA等HDAC抑制剂引起的HDAC抑制可在多种转化细胞中抑制肿瘤生长。传统的HDAC抑制剂缺乏同工型特异性,并且可以对非癌细胞产生毒性。因此,多胺衍生物,聚氨基异羟肟酸(PAHA)和聚氨基苯甲酰胺(PABA)类似物可用作HDAC抑制剂,以降低毒性,增加对染色质的亲和力并具有被多胺转运蛋白摄取的潜力。多胺部分与HDAC边缘区域的特异性相互作用也可以提高同工型的特异性。第一代聚氨基HDAC抑制剂,PAHAs在我们的实验室中较早合成,它们是有效的HDAC抑制剂,但转运蛋白的底物较差。因此,我们设计了第二代聚氨基HDAC抑制剂,其他PABA衍生物和等排同系物,以改善同工型特异性和多胺转运性。大多数具有各种结构特征的化合物在酶分析中似乎都抑制HDAC,其中一些对HDAC 1,HDAC 3、6和8以及在培养的肿瘤细胞中显示出相当高的选择性。在这个小的化合物文库中,与正常的乳腺癌上皮细胞相比,一种化合物对人乳腺肿瘤细胞显示出有希望的细胞毒性作用。;本论文中,我们报道了PABA和等位同源物的合成及其对HDAC亚型的活性以及它们的生物学评价。肿瘤细胞。

著录项

  • 作者

    Senanayake, M. D. Thulani.;

  • 作者单位

    Wayne State University.;

  • 授予单位 Wayne State University.;
  • 学科 Health Sciences Pharmacology.;Chemistry Pharmaceutical.
  • 学位 Ph.D.
  • 年度 2009
  • 页码 256 p.
  • 总页数 256
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-17 11:37:53

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号